FIRSTSOURCE SOLUTIONS LTD. Q1 FY27 Results

The quarter delivers a classic earnings quality test. Revenue surged 22.9% YoY to ₹2,725 crore — Firstsource's ninth consecutive double-digit year-on-year quarter and 11th straight sequential growth. But reported profit fell 2% YoY to ₹166 crore. The gap is not accounting noise; it is ₹72 crore in exceptional charges, centred on a ₹36 crore healthcare BPaaS deal termination, that ate the quarter's profitability.

Adjust for these items and the picture brightens: adjusted PAT reached ₹220 crore, up 31.2% YoY. Organic margin expansion remains intact — EBIT margin expanded 110 basis points to 12.4%, marking the seventh consecutive quarter of improvement and keeping the company on track for its 14–15% long-term target. On the surface, this looks like a one-time cleanup. But dig into the deal that triggered the charge, and the story darkens.

The healthcare BPaaS (Business Process as a Service) termination is not a small thing. Management had guided for a $50 million-plus run-rate deal that was in early-stage ramp. A client leadership change caused the new regime to reverse the technology transformation decision — a typical but painful dynamic in complex, multi-year outsourcing engagements. The ₹27 crore net charge covers partner ecosystem obligations and was taken conservatively.

What matters for forward earnings: management pegs this at a 1–1.5% FY27 revenue headwind. But what matters for investor confidence is what it signals about execution. Firstsource's core strategic narrative is a pivot toward 'Intelligence That Operates' — not just automating work, but owning delivery outcomes, implementing solutions, running operations, and driving transformation end-to-end. That model prizes deep domain expertise and stable client relationships. A transformative deal terminating mid-ramp, and a separate healthcare claims processing dispute that triggered a ₹28 crore regulatory indemnity charge, suggest the company is still learning to operate at this frontier.

Despite the exceptional charges, operating performance is solid. EBIT margin hit 12.4%, up 110 basis points year-on-year and 20 basis points sequentially. This is the seventh consecutive quarter of expansion, and it's tracking the company toward its 14–15% long-term target over 2–3 years. The expansion thesis rests on three legs: (1) AI platform traction — Kairos is now live at 14 of the top 20 US mortgage lenders and 10 of the top 15 US health plans, driving cost productivity and differentiation; (2) new geographic and capability expansion (South Africa, Canada, Middle East launches; US Retail, security services, marketing tech ramps); and (3) outcome-based commercial models that reward execution.

The risk: margin expansion may be running ahead of demand absorption. Q1 constant-currency revenue growth was 12.3% — the midpoint of guidance, not the upper range. For Firstsource to sustain 13% growth and offset the 1–1.5% healthcare headwind, new deal ramps must accelerate. Management claims Q1 was the 'best quarter in four quarters' for deal wins (4 large deals >$5M ACV, 12 new logos, 3 strategic at >$5M potential run-rate). But a quarter-over-quarter check shows the company needs those deals to ramp quickly — or growth will settle at the 10% lower end of guidance.

Zooming into the segment most affected: healthcare grew 11% YoY but declined 2% quarter-on-quarter in constant currency. Management attributes this to Medicare Advantage client program recalibrations following CMS rate adjustments — a 'pacing effect, not a demand shift.' But the segment's margins compressed from mid-teen levels to low double-digit, and it remains one-third of deal wins and revenue. The termination of a transformative BPaaS deal in this segment, coupled with a separate claims processing dispute, suggests execution fragility as the industry transitions from FTE-based to outcome-based commercial models.

Management's mitigation: new healthcare logos were added in Q1; the client base is diversified; and underlying relationships remain stable. But the margin compression is material enough that recovery timing matters for the 14–15% long-term EBIT target. If healthcare segment margins take longer to normalize, the path to the high end of that range lengthens.

The market's immediate response was a sell-off. On day 1 post-result, the stock fell 4.8%, and the decline accelerated: by day 3 it was down 4.88%, and by day 5 down 7.4%. This is not a pop-and-fade; it is a sustained repricing downward. The Street is not convinced by the adjusted profit narrative; it is focused on the headline miss and the deal termination as signals of execution risk.

At ₹267.1, the stock is down 26.58% from its all-time high of ₹363.8, though up 32.23% from its 52-week low. It trades below its 20-day simple moving average (₹283.41), above its 50-day average (₹262.09), and below its 200-day average (₹276.76). RSI is at 51.6 (neutral), and volume is decreasing — a pattern consistent with sustained institutional selling rather than the capitulation that often accompanies bottoms.

Ownership flows confirm this reading. Foreign institutional investors (FII) have trimmed exposure from 9.58% (Q1 FY26) to 8.38% (Q1 FY27), a decline of 48 basis points. Domestic institutional investors (DII) are flat, and promoter stake remains steady at 53.66%. The FII exit, concurrent with the Q1 result, suggests foreign investors are repricing for execution risk — or stepping back until the outcome-based model proves its delivery credentials.